News
CCC Diagnostics, Inc launches new website for the DirectHit® Test Panel for Breast Cancer
04/29/2010 –CCC Diagnostics, Inc. today launched their new website, directhittest.com to support the DirectHit® Test Panel for Breast Cancer. DirectHit is a vastly improved diagnostic test for breast cancer treatment that accurately predicts the tumor’s response to four commonly prescribed classes of anti-cancer drugs. Full Press Release
CCC Diagnostics Launches Improved Test for Breast Cancer Treatment
01/11/2010 –CCC Diagnostics, Inc., headquartered in Baltimore, Maryland, today announced that it has launched ”DirectHit test panel,” a vastly improved diagnostic test for breast cancer treatment that accurately predicts the tumor’s response to four commonly prescribed classes of anti-cancer drugs.
Full Press Release
John Hughes named CEO of CCCD
12/09/2009 – Comprehensive Cancer Cell Diagnostics (CCCD) has announced that its board of directors has named John Hughes to serve as the company’s chief executive officer and president. John brings an extensive business management and technical background that will be applied to marketing of DirectHit Tests
Mr. Hughes is also president and founder of Rhythm & Hues Studios, a leading producer of computer generated character animation and visual effects for entertainment and advertising. Headquartered in Los Angeles with additional facilities in Mumbai, Hyderabad and Kuala Lumpur, Rhythm & Hues has approximately 1000 employees worldwide. John is committed to providing a collaborative and supportive work environment in pursuit of the highest levels of technical excellence.
John will assume his new duties immediately. He will succeed Dr. Paul Ts’o, the founder of CCCD, who passed away earlier this month.
Gastrointestinal Cancer DRIT data presented at 2009 ADAPT Congress
9/23/09 – CCC Diagnostics in conjunction with Dr. Naimish Pandya of the University of Maryland Greenebaum Cancer Center and Dr. David Van Echo of HarborView Hospital in Baltimore, MD presented a poster describing developmental clinical studies of the DirectHit™ (DRIT) Gastrointestinal Cancer Panel at the ADAPT Congress in Washington D.C. The retrospective studies encompass prediction of response to drugs used in the treatment of esophageal, rectal, colon, pancreatic gastric and duodenal cancers.
CCCD Launches CLIA Compliant Diagnostic Testing Laboratory
09/04/2009, Baltimore , MD. Comprehensive Cancer Cell Diagnostics (CCCD), has launched a CLIA compliant testing laboratory to market the Breast Cancer DirectHitTM Panel as a diagnostic service. The DirectHit Panel™ Service analyzes an individual patient’s tumor in order to indicate the sensitivity / resistance to FDA-approved, National Comprehensive Cancer Network (NCCN) recommended chemotherapy drugs currently on the market.
Full Press Release
Monotherapy Preferred for Metastatic Breast Cancer
08/05/2009, Most women with metastatic breast cancer would receive greater benefits from sequential monotherapy rather than combination chemotherapy according to a report from the European School of Oncology Metastatic Breast Cancer Task force.
CCC Diagnostics publishes abstract on GI Cancer DRIT
06/03/2009 – CCC Diagnostics in conjunction with Dr. Naimish Pandya of the University of Maryland Greenebaum Cancer Center and Dr. David Van Echo of Harborview Hospital in Baltimore, MD published an abstract describing clinical studies of the GI cancer DRIT in the Journal of Clinical Oncology 27, 2009 (suppl; abstr e15079).
Expanded Breast Cancer DRIT data presented at 2009 ASCO Meeting
06/03/2009 – CCC Diagnostics in conjunction with Dr. Katherine Tkaczuk of the University of Maryland Greenebaum Cancer Center and Dr. David Van Echo of HarborView Hospital in Baltimore, MD presented a poster describing expanded Clinical studies of the Breast Cancer DRIT at the ASCO meeting held May 22 – June 2 in Orlando , FL.
DRIT clinical data presented at San Antonio Breast Conference
12/15/08 – CCC Diagnostics in conjunction with Dr. Katherine Tkaczuk of the University of Maryland Greenebaum Cancer Center presented a poster (#6075) describing clinical studies of the Breast Cancer DRIT at the San Antonio Breast Cancer Symposium held on December 10 – 14 2008.
CCC Diagnostics LLC receives CLIA Registration and Medical Lab Permit
10/21/2008 – CCC Diagnostics has received a Certificate of Registration from CLIA and a Medical Lab Permit from Maryland Department of Health and Mental Hygiene, Office of Health Care Quality.
TEDCO Approves Second Round of Funding for CCC Diagnostics
10/01/2008 – The Maryland Technology Development Corporation (TEDCO) has approved a second round of financing for CCC Diagnostics, LLC (CCCD) through the Maryland Technology Transfer Fund.
The award of $ 75,000 will support further clinical studies of CCCD’s Drug Response Indicator Test (DRIT) in collaboration with local hospitals and universities.
The Drug Response Indicator Test (DRIT) utilizes proprietary platform technology and delivers in one test a detailed profile of the tumor’s response rate to 5-7 FDA approved anticancer drugs. Armed with the advanced diagnostics, physicians are able to treat patients more effectively and with greater speed. CCCD’s commitment is to “saving lives and life savings.”
The fund is meant to encourage partnerships between Maryland businesses, universities and federal laboratories to bring new technologies to market.
Press Release
CCC Diagnostics and the University of Maryland awarded a second year of MIPS Funding
02/18/2008 – CCC Diagnostics and the University of Maryland have been awarded a second year of funding from the Maryland Industrial Partnerships in support of their project “Clinical Studies of the Drug Response Indicator Test”.
Article from the Baltimore Business Journal
DRIT Clinical Data Presented at 2008 ICACT Meeting
02/08/2008 – Dr. Katherine Tkaczuk of the University of Maryland Greenebaum Cancer Center gave an oral presentation describing CCC Diagnostics DRIT technology at the 19th International Congress on Anti-cancer Treatment in Paris, France.
CCC Diagnostics, LLC presents poster at San Diego AACR Conference
10/2007 – CCC Diagnostics LLC was invited to present a poster at the AACR-Special Conference in Cancer Research: Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications in San Diego, CA.
The University of Maryland and CCC Diagnostics Receive $410,477 in MIPS Funding
02/2007 – Baltimore-based CCC Diagnostics, LLC and the University of Maryland, Baltimore received $410,477 for clinical studies of the company’s diagnostic service for personalized chemotherapy, which measures a tumor’s resistance to commonly used cancer drugs.
Excerpt University of Maryland Press Release
The University of Maryland and CCC Diagnostics receive MIPS Funding
12/2006 – CCC Diagnostics and Dr. Katherine Tkaczuk of the University of Maryland Greenebaum Cancer Center have been selected to receive a Maryland Industrial Partnerships (MIPS) grant for their project “Clinical Studies of the Drug Response Indicator Test”.
CCC Diagnostics receives COSAT Funding
10/2006 – CCC Diagnostics, LLC has been chosen to receive funding from Johnson and Johnson’s Corporate Office of Science and Technology (COSAT) for development of the Drug Response Indicator Test. This funding will be administered as part of TEDCO’s Maryland Technology Transfer Fund (MTTF) award.
TEDCO Approves $75,000 award to CCC Diagnostics, LLC
09/2006 – The Maryland Technology Development Corporation (TEDCO) has approved an award of $ 75,000 to CCC Diagnostics, LLC (CCCD) through the Maryland Technology Transfer Fund. The funding will support clinical studies of CCCD’s Drug Response Indicator Test (DRIT).
The Drug Response Indicator Test (DRIT) utilizes proprietary platform technology and delivers in one test a detailed profile of the tumor’s response rate to 5-7 FDA approved anticancer drugs. Armed with the advanced diagnostics, physicians are able to treat patients more effectively and with greater speed. CCCD’s commitment is to “saving lives and life savings.”